Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Notebook: UK To Leave EU; Prices Attract Political Attention; Advanced Therapies Revamp

Executive Summary

Brexit vote creates uncertainty about biopharma policies in the UK and how local companies interact with the rest of the world;; antibiotic use decreases in several countries; high prices prompt European Commission review of industry incentives.

You may also be interested in...

UK Votes To Leave The EU – Where Next For The Life Sciences?

UK vote to leave the EU opens the prospect of years of negotiations over the union's future relationship with one of its most valued member states.

French Probe Possibility Of Manslaughter In Phase I Trial Case

Review will consider whether study fatality and serious injuries were a matter of "scientific chance" or "faults of a criminal nature"; separate evaluations will inform guidelines on first-in-human trials.

European Notebook: Clinical Trial Fatality; Affordable Medicines Debate; Physician Payment Disclosure

One death and five healthy volunteers hospitalized in a Phase I study in France; EU Council looks set to debate patient access to medicines; and the two Mercks set to continue litigation in Europe and the US over use of the Merck word, straining their 60-year-old agreement. Generics/biosimilar trade group adopts physician payment disclosure policy.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts